FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biochemistry. Described are isolated human antibodies, or humanised antibodies, or antigen-binging fragments which specifically bind with the growth/differentiation factor 8 (GDF8) and block the GDF8 activity. Claimed is a pharmaceutical composition, containing the described antibody or an antigen-binding fragment. Described is a method of inhibiting the GDF8 activity in a patient, including the introduction of the claimed pharmaceutical composition.
EFFECT: invention extends the means used in therapeutic methods of treating conditions or disorders, which are attenuated or improved as a result of GDF8 inhibition.
20 cl, 4 dwg, 27 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GDF8 HUMAN ANTIBODIES | 2011 |
|
RU2710156C2 |
| COMPOSITIONS AND METHODS FOR INCREASING BODY WEIGHT AND LEAN MUSCLE MASS USING LEPTIN RECEPTOR ANTAGONISTS, GDF8 AND ACTIVIN A | 2019 |
|
RU2818832C2 |
| MONOCLONAL ANTIBODY ABLE TO BIND TO SPECIFIC DISCONTINUOUS EPITOPE PLACED IN AD1 REGION OF HUMAN CYTOMEGALOVIRUS GB GLYCOPROTEIN, AND ITS ANTIGEN-BINDING FRAGMENT | 2010 |
|
RU2542472C2 |
| ANTI-ANGPTL3 ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2620064C2 |
| HUMAN ANTIBODIES TO Fel d1 AND METHODS OF USE THEREOF | 2013 |
|
RU2658491C2 |
| HUMANIZED TAU-ANTIBODY | 2013 |
|
RU2644242C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
| NEW ANTI-HUMAN TIE-2 ANTIBODY | 2015 |
|
RU2702553C2 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
